Fabian Hernandez
Medical · San Antonio, TXNPI 1407440712
Payments from drug & device makers
Across 316 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$874
- Amgen$686
- Novo Nordisk$505
- GSK$357
- Lilly USA, LLC$342
- AstraZeneca$327
- plus $2K from 42 others
What the payments were for
- Food & beverage$5,457100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,482 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $89,840 |
| JardianceEmpagliflozin | 45 | $75,882 |
| FarxigaDapagliflozin Propanediol | 45 | $52,937 |
| JanuviaSitagliptin Phosphate | 36 | $43,716 |
| EliquisApixaban | 25 | $27,669 |
| MyrbetriqMirabegron | 18 | $22,470 |
| TrulicityDulaglutide | 14 | $21,216 |
| MounjaroTirzepatide | 17 | $17,365 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,701 |
| VascepaIcosapent Ethyl | 14 | $11,972 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,015 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,335 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $5,768 |
| Fiasp PenfillInsulin Aspart (Niacinamide) | 15 | $4,603 |
| Omega-3 Acid Ethyl Esters | 22 | $3,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $505 | $89,84089 claims |
| Boehringer IngelheimJardiance | $199 | $75,88245 claims |
| AstraZenecaFarxiga | $327 | $52,93745 claims |
| MerckJanuvia | $107 | $43,71636 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $342 | $38,58131 claims |
| PfizerEliquis | $270 | $27,66925 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $22,47018 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $357 | $22,03641 claims |
| AbbVieSynthroid | $874 | $93313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in San Antonio
- Jose de la CerdaSan Antonio$1.1M
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- John KodoskySan Antonio$58K
- Amanda MillerSan Antonio$27K
- Felipe GalvanSan Antonio$26K
- Ledyenska BallesterosSan Antonio$22K
- Daniella ArellanoSan Antonio$15K
- Robert SchonhoffSan Antonio$14K
- Tanya GainesSan Antonio$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.